EGFR and cetuximab sensitivity of SCCUAT

Slides:

Advertisements

Similar presentations

MDM2: Oncogene Chan Lee. Discovery of MDM2: starting with tumor suppressor p53.

Advertisements

Advanced Cancer Topics Journal Review 4/16/2009 AD.

Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition–mediated cell death in K-ras mutant lung cancer.

IL-1β stimulates CXCL5 and CXCL8 gene expression and protein secretion in A549 cells in a time- and dose-dependent manner. IL-1β stimulates CXCL5 and CXCL8.

NRP2 represses IGF-IR expression and signaling.

Cetuximab treatment increases IFNγ receptor 1 expression.

Identification of TLOC1 and SKIL as tumor driver genes in 3q26.

CHK1 downregulation upon ERG overexpression.

NM-3 induces p21 levels and down-regulation of Cdk2 activity.

Inhibition of β-catenin by the Smad4/BMP pathway.

Role of HER2 in mediating acquired resistance to EGFR inhibition.

Expression changes of specific epigenetic-controlled tumor-related genes by the prenatal/maternal BSp treatment. qRT-PCR and Western blot analysis were.

High-level clonal amplification of FGFR2 predicts for sensitivity to FGFR inhibitor. High-level clonal amplification of FGFR2 predicts for sensitivity.

Knocking down Wnt3 increases the cells' response to trastuzumab and reduces cells' invasiveness. Knocking down Wnt3 increases the cells' response to trastuzumab.

P38 activation mediates chronic insulin-induced IRS1 and IRS2 degradation and is involved in myocardial insulin resistance in vitro. p38 activation mediates.

JAK3A572V mutation causes constitutive JAK3 activity and IL-2–independent proliferation of NKTCL cells. JAK3A572V mutation causes constitutive JAK3 activity.

Impaired in vitro adipogenic differentiation parallels elevated HDAC9 expression. Impaired in vitro adipogenic differentiation parallels elevated HDAC9.

Accumulation of ubiquitinated MDM2 following PN treatment requires the PIKK ATM. A, Western blots of nuclear extract proteins from ZR-75-1 cells treated.

NAPRT expression correlates to sensitivity for NAMPT inhibitors and to methylation of the CpG island of the NAPRT promoter. NAPRT expression correlates.

Fig. 6 RUNX/CBFB interaction inhibitor, Ro5-3335, significantly decreases mouse neurofibroma growth in vivo. RUNX/CBFB interaction inhibitor, Ro5-3335,

Quantification of NMT knockdown.

Aberrant regulation of HDAC2 and its association with malignant proliferation of human gastric cancer. Aberrant regulation of HDAC2 and its association.

Representative Western blot analyses of S-phase and other proteins from PC3 cell lysates obtained 3 days after oligomer (400 nm)/Lipofectin (15 μg/ml)

Gramicidin A (GA) decreases HIF protein expression in RCC cells.

Variation in dUTPase expression in cell lines.

PTENP1 serves as a ceRNA in the regulation of tumor growth in RCC

PTENP1 sensitizes renal cancer cells to chemotherapy.

Induction of CDCP1 is regulated by Ras in NSCLC cells.

A, cytotoxicity induced on HER2 3+ USC (ARK-2), HER2 0/1+ USC (ARK-4), and ARK-2/ARK-4 cocultures with 1 μg/mL of SYD985, T-DM1, and ADC isotype control.

Identification of NSC as a FADD-kinase inhibitor.

CDDO-Me induces apoptosis independent of Bcl-2 level as well as p53 status in human NSCLC cells. CDDO-Me induces apoptosis independent of Bcl-2 level as.

A, GP and GR epithelial tumor cells are equally responsive to gefitinib. A, GP and GR epithelial tumor cells are equally responsive to gefitinib. Equal.

CHCHD2 and EGFR protein expression in NSCLC

TDP1 and TOP1 protein levels correlate positively with TDP1 and TOP1 mRNA levels in colorectal cancer cell lines. TDP1 and TOP1 protein levels correlate.

Histone modification status at the Tβ4 promoter and at the protein level in the HuH7 sublines. Histone modification status at the Tβ4 promoter and at the.

Discovery of Gö6976-related potent reversible EGFR T790M inhibitors.

Changes of gene expression induced by 1 mmol/L valproic acid in vitro.

Curcumin suppresses the expression of antiapoptotic proteins in multiple myeloma cells. Curcumin suppresses the expression of antiapoptotic proteins in.

HNSCC and NSCLC cell lines display differential sensitivities to cixutumumab in the 3D mimic condition. HNSCC and NSCLC cell lines display differential.

Biological effects of BRAF silencing: growth curves of A375 (A) and ARO (B) cell lines in the absence or presence of doxycycline. Biological effects of.

Antitumor effects of celastrol in vitro and in vivo.

Microarray analysis of global gene expression profiles of PC-3 and derivative cell lines. Microarray analysis of global gene expression profiles of PC-3.

Endogenously produced n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in vivo. Endogenously produced n-3 PUFAs inhibit endometrial cancer.

Analysis of mRNA and protein levels of Loricrin, COMP, CXCL9, KRT19, and CYP 3A5 genes in OSFs compared with normal controls. Analysis of mRNA and protein.

Effects of EGCG on the anchorage-independent growth of EFT cells.

Effects of HDAC2 inactivation on the invasive potential of human gastric cancer cells. Effects of HDAC2 inactivation on the invasive potential of human.

Bortezomib induces an NRF2 signature and NRF2 protein in tumor cells from leukemic MCL. Gene sets regulated by bortezomib (Supplementary Tables S3 and.

PTPH1 depends on its catalytic activity to increase ER nuclear accumulation and to enhance breast cancer sensitivity to TAM. A, effects of PTPH1 and PTPH1/DA.

Platinum-based chemotherapy increased TXNIP expression, and overexpression of TXNIP enhanced the effectiveness of this therapy. Platinum-based chemotherapy.

A, expression of p53 downstream mediator p21.

Changes in signal transduction pathway induced by gefitinib.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

Tivantinib does not inhibit MET function.

SAHA blocks IR-induced increase of RAD51 protein in MM cells.

Expression data from genes involved in regulation of transit through the cell cycle in response to treatment with E2 and OHT. A. Expression data from genes.

Levels and activity of c-myc are increased in a series of stably transfected DAOY and UW228 medulloblastoma cell lines. Levels and activity of c-myc are.

Expression and induction of HER2 and HPSE in 231BMBC cells.

BEZ235 induces accelerated senescence after radiation (IR) in vitro.

Identification of RASA1- and NF1-mutated lung cancer cell lines in the CCLE dataset (accessed via the cBioPortal for Cancer Genomics at

Establishment of HeLa/rtTAA/TRE-N1-IC cell line.

MYC expression is correlated with dasatinib sensitivity in cancer cell lines and in vivo. MYC expression is correlated with dasatinib sensitivity in cancer.

Increased growth factor receptor expression in lungs and tumors of hypoxic mice. Increased growth factor receptor expression in lungs and tumors of hypoxic.

Effect of dexamethasone on PCDGF/GP88 mRNA and protein expressions and effect of PCDGF/GP88 on dexamethasone-induced cell death. Effect of dexamethasone.

CPGL is a growth suppressor in pancreatic cancer cell lines.

Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.

PLK1 is a crucial downstream effector of PDK1 for MYC activation and cell survival. PLK1 is a crucial downstream effector of PDK1 for MYC activation and.

Effect of SFN on the total activity and protein expression of HDACs in JB6 P+ cells. Effect of SFN on the total activity and protein expression of HDACs.

Loss of NQO1 expression inhibits invasion of NSCLC

Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.

CREB1 binds at the proximal region of the TGFB2 promoter and induces its transcriptional activation. CREB1 binds at the proximal region of the TGFB2 promoter.

Presentation transcript:

EGFR and cetuximab sensitivity of SCCUAT EGFR and cetuximab sensitivity of SCCUAT. A, EGFR mRNA levels in biopsies from tumors of the indicated organs published at cBioPortal for Cancer Genomics (55, 56). EGFR and cetuximab sensitivity of SCCUAT. A, EGFR mRNA levels in biopsies from tumors of the indicated organs published at cBioPortal for Cancer Genomics (55, 56). B, EGFR mRNA levels in commercial available cell lines originating from esophagus or head and neck published at cBioPortal for Cancer Genomics (55, 56). RMA, robust multiarray average. Arrows, EGFR gene amplification. *, cell lines included in the present study. C, immunoblot analyses of pEGFR(Tyr1068) and EGFR in selected SCCUAT cell lines. D, EGFR gene copy number normalized to Multicopy Reference, EGFR mRNA normalized to GAPDH, EGFR protein levels normalized to β-actin, and pEGFR(Tyr1068) levels normalized to β-actin. Quantification data of EGFR and pEGFR(Tyr1068) are presented as average of three independent experiments ±SEM. E, growth inhibition of selected SCCUAT cell lines in vitro induced by 50 μg/mL cetuximab after 96 hours of treatment using WST-1 in a viability assay. Mutation status for key oncogenes: black, mutation; gray, unknown mutation status; and white, wild-type. F, correlation blots of the level of cetuximab-induced growth inhibition vs. EGFR copy number, EGFR mRNA, EGFR protein expression, or pEGFR(Tyr1068) expression. The data have been normalized as described in D. Ida Kjær et al. Mol Cancer Ther 2016;15:1614-1626 ©2016 by American Association for Cancer Research